LEADER 01557nam  2200409z- 450 
001 9910694344803321
005 20080910092237.0
035   $a(CKB)5860000000030788
035   $a(BIP)015768141
035   $a(EXLCZ)995860000000030788
100   $a20220406c2007uuuu  -u-         -
101 0 $aeng
200 10$aPatient safety and quality issues in end stage renal disease treatment $ehearing before the Committee on Ways and Means, U.S. House of Representatives, One Hundred Ninth Congress, second session, December 6, 2006
215   $a1 online resource (iii, 94 p.) $cill
311   $a0-16-078967-2 
517   $aPatient safety and quality issues in end stage renal disease treatment 
606   $aChronic renal failure$xTreatment$zUnited States
606   $aChronic renal failure$xGovernment policy$zUnited States
606   $aMedicare$xQuality control
606   $aDrugs$xPrices$zUnited States
606   $aPharmaceutical services insurance$zUnited States
610   $aMedical care
610   $aChronic renal failure
610   $aDrugs
610   $aHealth insurance
610   $aLaw
610   $aMedical
610   $aBusiness & economics
615  0$aChronic renal failure$xTreatment
615  0$aChronic renal failure$xGovernment policy
615  0$aMedicare$xQuality control.
615  0$aDrugs$xPrices
615  0$aPharmaceutical services insurance
906   $aBOOK
912   $a9910694344803321
996   $aPatient safety and quality issues in end stage renal disease treatment$93133460
997   $aUNINA